Últimas noticias sobre Humana (NYSE:HUM) Bolsa

HUMANA INC

Humana

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Usd,Dollar,Banknote,Is,Torn,With,Recession,Wording,On,Red

Analyst Color

Equities

Macro Economic Events

Econ #s

Economics

Analyst Ratings

Tech

ETFs

FSLR

GRMN

NCLH

PLTR

SBUX

SCCO

SHOP

SMCI

TEAM

El PIB de EE.UU. cae un 0,3 % en el primer trimestre de 2025. Wall Street retrocede y aumentan los temores de recesión e inflación.

EE.UU. entra en contracción económica: PIB cae un 0,3% y Wall Street reacciona con fuertes caídas

Piper Sandler analyst Jessica Tassan maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $288 to $272.

News

Price Target

Piper Sandler Maintains Neutral on Humana, Lowers Price Target to $272

EXAS

Exact Sciences And Humana Collaborate To Enhance Early Detection of Colorectal Cancer With FDA-Approved Cologuard Plus Test

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$10.00</td>
<td>$35.0K</td>
<td>3.3K</td>
<td>8.7K</td>
</tr>
<tr>
<td>ALHC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$12.50</td>
<td>$250.0K</td>
<td>15.3K</td>
<td>3.8K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/01/25</td>
<td>$182.50</td>
<td>$69.5K</td>
<td>3.3K</td>
<td>918</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.50</td>
<td>$131.5K</td>
<td>15.7K</td>
<td>518</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/08/25</td>
<td>$73.00</td>
<td>$79.8K</td>
<td>94</td>
<td>392</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$175.00</td>
<td>$44.4K</td>
<td>14.4K</td>
<td>321</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$85.00</td>
<td>$48.7K</td>
<td>180</td>
<td>310</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$23.00</td>
<td>$40.2K</td>
<td>810</td>
<td>257</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$220.00</td>
<td>$170.0K</td>
<td>183</td>
<td>220</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$45.00</td>
<td>$48.0K</td>
<td>1.5K</td>
<td>208</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For REPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>), we notice a call option sweep that happens to be bearish, expiring in 114 day(s) on November 21, 2025. This event was a transfer of 250 contract(s) at a $10.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3310 open contracts at this strike prior to today, and today 8715 contract(s) were bought and sold. 
• For ALHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on August 15, 2025. This event was a transfer of 2000 contract(s) at a $12.50 strike. The total cost received by the writing party (or parties) was $250.0K, with a price of $125.0 per contract. There were 15302 open contracts at this strike prior to today, and today 3811 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on August 1, 2025. Parties traded 499 contract(s) at a $182.50 strike. This particular put needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $69.5K, with a price of $142.0 per contract. There were 3330 open contracts at this strike prior to today, and today 918 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bearish sentiment. It expires in 170 day(s) on January 16, 2026. Parties traded 500 contract(s) at a $22.50 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $131.5K, with a price of $263.0 per contract. There were 15788 open contracts at this strike prior to today, and today 518 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 9 day(s) on August 8, 2025. Parties traded 235 contract(s) at a $73.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $79.8K, with a price of $340.0 per contract. There were 94 open contracts at this strike prior to today, and today 392 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on October 17, 2025. This event was a transfer of 200 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $44.4K, with a price of $222.0 per contract. There were 14487 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option trade with bullish sentiment. It expires in 233 day(s) on March 20, 2026. Parties traded 14 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $48.7K, with a price of $3480.0 per contract. There were 180 open contracts at this strike prior to today, and today 310 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on August 15, 2025. This event was a transfer of 244 contract(s) at a $23.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $165.0 per contract. There were 810 open contracts at this strike prior to today, and today 257 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bullish, expiring in 534 day(s) on January 15, 2027. This event was a transfer of 25 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $170.0K, with a price of $6800.0 per contract. There were 183 open contracts at this strike prior to today, and today 220 contract(s) were bought and sold. 
• Regarding BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we observe a call option sweep with bearish sentiment. It expires in 16 day(s) on August 15, 2025. Parties traded 160 contract(s) at a $45.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $48.0K, with a price of $300.0 per contract. There were 1591 open contracts at this strike prior to today, and today 208 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

ACAD

ALHC

BBIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

REPL

10 Health Care Stocks Whale Activity In Today's Session

U.S. stocks inched higher midday Wednesday, as investors digested upbeat economic data while keeping an optimistic tone ahead of the Federal Reserve's policy decision and a wave of key tech earnings <a href="https://www.benzinga.com/markets/earnings/25/07/46693997/wall-street-earnings-preview-microsoft-apple-meta-amazon-mastercard-visa">due after the bell. </a>
<ul class="wp-block-list">
<li>The QQQ ETF is on track for a fourth consecutive monthly gain. <a href="https://www.benzinga.com/quote/QQQ">See the chart here.</a></li>
</ul>
The S&amp;P 500 rose 0.2%, the Nasdaq added 0.4%, and the Dow Jones hovered near the flatline. Small-cap stocks outperformed, with the Russell 2000 up 0.6%. 
Markets widely expect the Federal Reserve to keep rates steady at 4.25%-4.50%, but with two policymakers already showing preference for a cut, the decision could mark the most divided vote since 1993.
On the trade front, former President Donald Trump announced a new 25% tariff on Indian imports, set to take effect Aug. 1. 
Advance GDP data showed the U.S. economy grew at an annualized 3.0% in the second quarter of 2025, a sharp rebound from the previous quarter's 0.5% contraction and well above the 2.4% consensus, powered by strong consumer spending and a decline in imports. 
In the labor market, private payrolls rose by 104,000 in July, the strongest gain since March and a solid beat on the 75,000 forecast—reversing a contraction in June. 
Commodities were in focus as WTI crude extended its rally, surging 1.5% on the day to hit $70 a barrel, driven by geopolitical tensions following Trump's new 10-day ultimatum to Russia over peace talks with Ukraine. The three-day gain now totals over 8%.
Gold slipped 1% to $3,290 per ounce as the U.S. dollar strengthened on the back of robust economic data. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $118,000.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.27</td>
<td>0.6%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,396.45</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,384.59</td>
<td>0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,654.85</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:05 p.m. ET</figcaption></figure>
According to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) inched 0.1% higher to $584.81.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) flattened at $446.50.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.3% to $569.07.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 0.7% to $224.19.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1%.</li>
</ul>
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h2>
<ul class="wp-block-list">
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) climbed 2.3%, poised to break a seven-day losing streak, after JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) announced a partnership with the crypto exchange that will allow Chase credit card holders to fund their Coinbase wallets and purchase cryptocurrencies. </li>
<li>Stocks moving on earnings reports included: 
<ul class="wp-block-list">
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) up 0.8%</li>
<li>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) flat</li>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) up 1.2%</li>
<li>Automatic Data Processing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) up 1.9%</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) up 0.7%</li>
<li>Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) up 2.0%</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) down 7.8%</li>
<li>Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) down 6.0%</li>
<li>Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) down 2.0%</li>
<li>Republic Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) down 5.0%</li>
<li>American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) up 3.8%</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) up 1.6%</li>
<li>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) down 5.5%</li>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) up 7.2%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) up 3.2%</li>
<li>Verisk Analytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) down 4.8%</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) up 2.3%</li>
<li>WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) up 0.5%</li>
<li>Tradeweb Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) up 4.9%</li>
<li>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) down 4.9%</li>
<li>Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) down 1.0%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) down 8.8%</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) up 7.4%</li>
<li>Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPN#NASDAQ">EXPN</a>) up 5.1%</li>
<li>Smurfit Westrock plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMUR#NYSE">SMUR</a>) down 2.1%</li>
<li>PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) down 4.9%</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) up 3.6%</li>
<li>Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) down 4.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) up 21.2%</li>
<li>Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) up 0.9%</li>
</ul>
</li>
</ul>
<h2 class="wp-block-heading">Stocks slated to report earnings after the close:</h2>
<ul class="wp-block-list">
<li>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</li>
<li>American Water Works Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>)</li>
<li>Antero Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>)</li>
<li>AvalonBay Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>)</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>)</li>
<li>C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>)</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)</li>
<li>Cognizant Technology Solutions Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>)</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>)</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>)</li>
<li>Equinix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>)</li>
<li>Everest Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>)</li>
<li>Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>)</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>)</li>
<li>Fair Isaac Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>)</li>
<li>FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>)</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)</li>
<li>GFL Environmental Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>)</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>)</li>
<li>Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>)</li>
<li>Host Hotels &amp; Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>)</li>
<li>Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>)</li>
<li>Invitation Homes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>)</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>)</li>
<li>Mid-America Apartment Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>)</li>
<li>Prudential Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>)</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>)</li>
<li>QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)</li>
<li>The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>)</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>)</li>
<li>UDR, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>)</li>
<li>Ventas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>)</li>
<li>VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>)</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</li>
</ul>
Now Read
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46720292/us-gdp-q2-economy-us-trump-fed-interest-rates-dollar">US Economy Roars Back With 3% Growth, Handing Trump A Timely Victory </a></li>
</ul>
Image: Shutterstock

Large Cap

$BTC

ACGL

BKNG

CFLT

CHRW

COIN

CTSH

CVNA

SPDR Dow Jones Industrial Average ETF Trust

DXCM

EBAY

EQIX

EXPN

FFIV

FICO

GEHC

HOLX

INVH

LRCX

MDLZ

MSFT

ODFL

QCOM

SMUR

TEVA

VICI

VRSK

Stocks Rise Ahead Of Fed Meeting, Oil Jumps To $70: What's Moving Markets Wednesday?

As the healthcare landscape evolves with new legislation and shifting demographics, Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is adapting to these changes through strategic adjustments. This adaptability is reflected in their second-quarter earnings report, which exceeded analysts&#8217; expectations despite a decline in adjusted EPS <a href="https://www.benzinga.com/calendars/earnings">compared to last year.</a>
Humana on Wednesday posted a second-quarter adjusted EPS of $6.27, down from $6.96 a year ago, beating the consensus of $5.90.
<ul class="wp-block-list">
<li>HUM stock is on the move, climbing higher. <a href="https://www.benzinga.com/quote/HUM" target="_blank" rel="noreferrer noopener">See the chart here.</a></li>
</ul>
<h2 class="wp-block-heading">Humana&#8217;s Earnings Beat Raises Eyebrows</h2>
The company reported sales of $32.39 billion, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46715297/humana-reports-second-quarter-2025-financial-results-raises-full-year-2025-adjusted-eps-and-revenu" rel="noreferrer noopener">consensus of $31.89 billion</a>.
Increased revenue was driven by higher per-member Medicare and state-based contract premiums, with the Medicare increase primarily resulting from an increased direct subsidy due to the Inflation Reduction Act (IRA), as well as membership growth in the company&#8217;s state-based contracts and stand-alone PDP businesses.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46503726/humana-shares-decline-after-losing-medicare-bonus-payment-lawsuit-what-to-know" target="_blank" rel="noreferrer noopener">Humana Shares Decline After Losing Medicare Bonus Payment Lawsuit: What To Know</a>
Humana&nbsp;ended the quarter with 14.84 million in total medical membership, down from 16.19 million a year ago.
Individual Medicare Advantage membership&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/b62138dc-721b-460e-8579-557be91ba7da" rel="noreferrer noopener">reached</a> 5.23 million, down from 5.62 million a year ago.
<h2 class="wp-block-heading">Can Membership Declines Signal Deeper Issues?</h2>
Medicare stand-alone PDP membership was 2.43 million, up from 2.34 million the previous year. The insurance segment benefit ratio of 89.9% aligns with the previously disclosed expectation of approximately 90%.
Guidance: Humana expects 2025 adjusted earnings of approximately $17 per share compared to prior guidance of $16.25 and the consensus of $16.36, supported by solid execution and results.
Updated adjusted EPS guidance now contemplates approximately $100 million of incremental investments to improve member and patient outcomes and support operational excellence, positioning the company for long-term success.
Revenue is expected to be at least&nbsp;$128 billion in 2025, compared to the consensus estimate of $126.72 billion and the previous&nbsp;guidance&nbsp;of&nbsp;$126 billion—$128 billion, supported by better than anticipated individual MA membership and higher than expected payor-agnostic patient growth and script volumes in CenterWell, the company <a target="_blank" href="https://humana.gcs-web.com/static-files/ec7b3f73-7995-4441-afab-90093d8798e9" rel="noreferrer noopener">said</a> in prepared remarks on Wednesday.
<h2 class="wp-block-heading">How The Inflation Reduction Act Impacts Revenue</h2>
Sales guidance includes insurance segment sales of at least $123 billion, compared to <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/45108509/humana-does-not-alter-2025-outlook-despite-sales-miss-and-medicare-membership-decline" rel="noreferrer noopener">prior guidance of $121 billion—$123 billion</a>, and center-well segment sales of at least $21.5 billion, up from the previous range of $20.5 billion—$21.5 billion.
The insurer anticipates a 2025 decline of &#8216;up to 500,000&#8217; individual MA members, compared to the previous expectation of a decline of &#8216;approximately 550,000&#8217; members.
For 2025, Humana expects its insurance segment&#8217;s benefit ratio guidance of approximately 90.1-90.5%.
HUM Price Action: Humana shares were up 8.33% at $251.99 at the time of publication on Wednesday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46719164/vans-parent-vf-corp-eyes-growth-as-turnaround-gains-traction" target="_blank" rel="noreferrer noopener">Vans Parent VF Corp Eyes Growth As Turnaround Gains Traction</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

Humana Boosts 2025 Profit Guidance, Plans $100 Million In Strategic Investments

Humana FY2025 GAAP EPS Expected To Be Approximately $13.77' From Previous Estimate Of Approximately $14.68 And $14.90 Est

Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percentRevises FY 2025 individual Medicare Advantage membership guidance to now anticipate a decline of 'up to 500,000 members' from
<ul>
<li>Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent</li>
<li>Revises FY 2025 individual Medicare Advantage membership guidance to now anticipate a decline of 'up to 500,000 members' from previous guidance of a decline of 'approximately 550,000'
<ul>
<li>Expected membership decline inclusive of the impact of exiting certain unprofitable plans and counties</li>
<li>Remains confident in 2025 pricing strategy as the company prioritizes benefit structure that is expected to drive sustainable, long-term value creation</li>
</ul>
</li>
</ul>

Humana FY2025 Adj. EPS Expected To Be Approximately $17 vs. Approximately $16.25 Prior Guidance And $16.36 Est; FY2025 Revenue To Be At Least $128B vs $126.717B Est And Previous Guidance Of $126B-$128B

WIIM

Humana shares are trading higher after the company better-than-expected Q2 financial results.

Humana Q2 2025 Adj. EPS $6.27 Beats $5.90 Estimate, Sales $32.388B Beat $31.884B Estimate

ALGN

ALKT

AMRN

AMSC

ANIK

APLD

ARCB

AWRE

AXTA

BBDO

BLCO

BLFY

BLKB

BSBR

BXMT

CGNX

CHEF

CHKP

CLMB

CLVT

CMCO

CNMD

CNXN

COCO

COMP

CPSH

CRTO

CTOS

New Oriental Education & Technology Group

ENTG

EOSE

ETSY

EVTC

EZPW

FBRT

FORM

FRGE

FVRR

Earnings Scheduled For July 30, 2025

<a href="https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c">https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c</a>

CLOV

EHTH

ELEV

GOCO

' Medicare Part D Drug Plan Premiums Set to Rise'- WSJ

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
Wall Street rallied as a wave of new trade deals — including agreements with Japan, Indonesia, and the Philippines — fueled optimism, pushing the S&amp;P 500 and Nasdaq to fresh record highs. President Donald Trump escalated pressure on Federal Reserve Chair Jerome Powell during an in-person visit, demanding lower rates in light of trade easing.
Investor sentiment remained upbeat despite rising political friction. Treasury yields increased modestly on speculation about compromised Fed independence, amid calls from influential voices like Mohamed El‑Erian suggesting Powell resign to preserve central bank autonomy.
Looking ahead, markets are watching progress in U.S.–EU trade negotiations — including a meeting between Trump and Ursula von der Leyen — and upcoming economic data. Investor focus is also on whether pressure on the Fed may influence its rate path or institutional reputation.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46607168/google-stock-roars-as-analysts-race-to-raise-price-targets">"Google stock roars as analysts race to raise price targets"</a>, by Chris Katje, reports that Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) delivered its tenth straight quarter of earnings beats — including $96.43 billion in Q2 revenue and $2.31 EPS — prompting firms to raise their price targets on strength in AI‑driven growth across Cloud, Search, and Ads.
<a href="https://www.benzinga.com/markets/earnings/25/07/46587855/t-mobile-stock-climbs-after-q2-results-crushed-growth-records">"T‑Mobile stock climbs after Q2 results ‘crushed' growth records"</a>, by Erica Kollmann, reports that T‑Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) beat Q2 estimates with $2.84 EPS and $21.13 billion in revenue, added a record 1.7 million postpaid customers — driving upwardly revised FY2025 guidance — and sent shares higher.
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46590824/lendingtree-stock-climbs-as-company-signals-stronger-growth-ahead">"LendingTree stock climbs as company signals stronger growth ahead"</a>, by Akanksha Bakshi, reports that LendingTree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) shares rose after the company highlighted improving lead quality and customer acquisition metrics — citing momentum in core marketplaces and new verticals as drivers of expected stronger growth ahead.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/markets/earnings/25/07/46559708/capital-one-stock-climbs-on-strong-q2-eps-despite-revenue-miss">Capital One Stock Climbs On Strong Q2 EPS, Despite Revenue Miss</a>
<a href="https://www.benzinga.com/markets/earnings/25/07/46618339/coursera-stock-rockets-20-higher-after-q2-earnings-report-heres-why">Coursera Stock Rockets 20% Higher After Q2 Earnings Report: Here's Why</a>
<a href="https://www.benzinga.com/markets/earnings/25/07/46588567/quantumscape-announces-better-than-expected-q2-results-expands-collaboration-with-powerco">QuantumScape Announces Better-Than-Expected Q2 Results, Expands Collaboration With PowerCo</a>

The Bears
<a href="https://www.benzinga.com/markets/earnings/25/07/46612958/molina-healthcare-stumbles-cigna-cvs-humana">"Centene, Cigna, Others Drop As Molina's Results Rattle Sector"</a>, by Vandana Singh, reports that Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) missed Q2 earnings expectations — posting $5.48 EPS vs. $6.21 consensus — even as revenue topped estimates, and slashed its 2025 EPS guidance to just over $19 (from $21.50-$22.50), sending shares of Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and others sharply lower on concerns about medical cost trends and sector-wide risk.
<a href="https://www.benzinga.com/news/fda/25/07/46544331/fda-rejects-replimunes-blood-cancer-drug-stock-sinks">"FDA rejects Replimune's blood cancer drug, stock sinks"</a>, by Erica Kollmann, reports that Replimune Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares plunged after the FDA rejected the company's investigational oncolytic virus therapy for blood cancers, citing deficiencies in clinical data and risk-benefit analysis — prompting investor concern about future development timelines and capital needs.
<a href="https://www.benzinga.com/markets/earnings/25/07/46589727/viking-therapeutics-stock-slides-after-company-misses-q2-earnings-estimates">"Viking Therapeutics stock slides after company misses Q2 earnings estimates"</a>, by Adam Eckert, reports that Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares tumbled after reporting a Q2 loss of $0.58 per share — wider than the expected $0.46 loss — while R&amp;D expenses surged to $60.2 million and the company ended the quarter with $808 million in cash.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46606784/c3-ai-stock-is-tumbling-thursday-whats-going-on">C3 AI Stock Is Tumbling Thursday: What's Going On?</a>
<a href="https://www.benzinga.com/markets/large-cap/25/07/46641084/wall-street-stock-bubble-2025">Is A Stock Market Crash Imminent? Bubble Warnings Grow Louder</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46569958/mara-holdings-stock-is-moving-lower-wednesday-heres-why">MARA Holdings Stock Is Moving Lower Wednesday: Here's Why</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

Markets

COUR

GOOGL

MARA

TMUS

TREE

VKTX

Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets

Baird analyst Michael Ha maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $300 to $297.

Baird Maintains Neutral on Humana, Lowers Price Target to $297

Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) missed Wall Street expectations in its second-quarter earnings report Wednesday, triggering a selloff across the <a href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance">healthcare insurance sector</a>. 
Shares of Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Tenet Healthcare Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) all traded lower Thursday as investors reacted to Molina's earnings miss and lowered 2025 guidance, citing rising medical costs and utilization trends.
What Happened: On Wednesday after close, Molina reported second-quarter adjusted earnings of $5.48 per share, missing the consensus of $6.21 and the preliminary expectation of approximately $5.50 per share.
The insurance company reported sales&nbsp;of $11.43 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.93 billion</a>.
Molina&#8217;s second quarter results reflect a &#8220;challenging medical cost trend environment," said Joseph Zubretsky, President and Chief Executive Officer. "The current earnings pressure we are experiencing results from what we believe to be a temporary dislocation between premium rates and medical cost trend which has recently accelerated.&#8221;
Molina is still performing near its long-term target ranges, and the long-term outlook remains the same, he added.
<ul class="wp-block-list">
<li>The consolidated Medical Care Ratio (MCR) for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46586998/molina-healthcare-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">second quarter of 2025 was 90.4%</a>.</li>
<li>The Medicaid MCR was 91.3%. The company experienced medical cost pressure due to continued utilization of behavioral health, pharmacy, and inpatient and outpatient services.</li>
<li>The Medicare MCR was 90.0%, reflecting higher utilization among high-acuity members, particularly for long-term services, supports, and pharmacy.</li>
<li>The Marketplace MCR was 85.4%. Approximately 300 basis points were due to prior-year member reconciliations and a higher "new store" MCR related to the ConnectiCare acquisition.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers" target="_blank" rel="noreferrer noopener">Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?</a>
On Wednesday, Molina further revised its 2025 earnings guidance from $21.50-$22.50 to over $19 per share.
Notably, Centene withdrew its 2025 GAAP and adjusted diluted EPS guidance. This stems from its initial review of 2025 industry data from Wakely, an <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" target="_blank" rel="noreferrer noopener">independent actuarial firm</a>.
Molina Healthcare forecasts fiscal 2025 sales&nbsp;of $44 billion compared to the consensus of $44.19 billion.
It forecasts a 2025 consolidated MCR of 90.2%, with Medicaid MCR of 90.9%, Medicare MCR of 90% and Marketplace MCR of 85.1%.
Readers should also note that the largest insurance company, UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), is also trading lower on Thursday. In an SEC filing on Thursday, the company said it has now begun complying with the Department's formal criminal and civil requests. UnitedHealth says it has full confidence in its practices and is committed to working cooperatively with the <a target="_blank" href="https://www.benzinga.com/news/legal/25/07/46605691/unitedhealth-under-federal-scrutiny-reaffirms-integrity-of-its-medicare-operations" rel="noreferrer noopener">Department throughout this process</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/restaurants/25/07/46606785/chipotle-mexican-grill-q2-sales-decline-june-july-boost-keeps-analysts-bullish" target="_blank" rel="noreferrer noopener">Chipotle Mexican Grill Q2 Sales Decline, June-July Boost Keeps Analysts Bullish</a></li>
</ul>
Image: Shutterstock

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Centene, Cigna, Others Drop As Molina's Results Rattle Sector

Shares of health insurers are trading lower in sympathy with Molina Healthcare, which issued soft guidance. The sector may also be under pressure after UnitedHealth said  it has now begun complying with the DOJ's formal criminal and civil requests.

Shares of Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) are trading lower Friday after the company lost a legal battle over Medicare bonus payments. 
What To Know: A Texas district court dismissed Humana's lawsuit, upholding the government's decision to downgrade the company's Medicare quality ratings. The ruling is expected to reduce Humana's Medicare bonus payments beginning in 2026, posing a risk to future profitability. Following the court's decision, Humana shares dropped as much as 7.5% earlier in the session before settling lower, <a href="https://www.bloomberg.com/news/articles/2025-07-18/humana-loses-bid-to-reverse-medicare-bonus-payment-cut?embedded-checkout=true">according to Bloomberg.</a>
The ruling adds to growing scrutiny of the private health insurance industry, particularly concerning claim denials. Recent data compiled by Komodo Health for <a href="https://www.nytimes.com/2025/07/18/health/health-insurance-prescription-claim-denials.html#:~:text=Prescription%20drug%20denials%20by%20private,nation's%20private%20health%20insurance%20system.">The New York Time</a>s revealed a 25% increase in prescription drug denials by private insurers between 2016 and 2023. 
Humana's denial rates reportedly declined in the last two years of the study period but the industry as a whole saw higher rejection rates.
HUM Price Action: Humana shares were down 1.66% at $219.85 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46499876/wall-street-friday-stocks-today-trump-netflix-earnings">Stocks Slip As Netflix Fails To Impress, Bitcoin Eyes Negative Week: What&#8217;s Moving Markets Friday?</a></li>
</ul>
Image Via Shutterstock.

Humana Shares Decline After Losing Medicare Bonus Payment Lawsuit: What To Know

<a href="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c" title="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c">https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c</a>

Biotech

Reported Earlier: 'Obamacare Insurers Seek Double-Digit Premium Hikes Next Year; Some Enrollees Could Be Hit With Increases Of More Than 20% Because Of Federal Changes And Higher Health Expenses' - WSJ Exclusive

https://www.nytimes.com/2025/07/18/health/health-insurance-prescription-claim-denials.html#:~:text=Prescription%20drug%20denials%20by%20private,nation's%20private%20health%20insurance%20system.

Reported Earlier: 'Health Insurers Are Denying More Drug Claims, Data Shows' - NY Times

Humana shares are trading lower after the company reportedly lost its Medicare bonus payment lawsuit.

<a href="https://www.bloomberg.com/news/articles/2025-07-18/humana-loses-bid-to-reverse-medicare-bonus-payment-cut?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-18/humana-loses-bid-to-reverse-medicare-bonus-payment-cut?embedded-checkout=true</a>

'Humana Loses Bid to Reverse Medicare Bonus Payment Cut'- Bloomberg

Press Releases

Humana Expands Science-Based Targets with New SBTi-Validated Target

National Mall of Pickleball Returns for Third Year with Expanded Footprint and New, Central Location

Humana Launches Medicaid Plan in Virginia

The Villages Health ("TVH") Announces Strategic Restructuring and Agreement to be Acquired by CenterWell

Humana Foundation Responds to Central Texas Flood Tragedy with $500,000 in Recovery Support

Humana Inc. to Release Second Quarter 2025 Results on July 30, 2025

Inaugural Humana Cognitive Games to Celebrate Healthy Aging and Inspire Whole-Person Wellness

Humana Simplifies Access to Coverage and Care Information

Humana Accelerates Efforts to Eliminate Prior Authorization Requirements to Ensure a Faster, More Seamless Process

Humana Reports Second Quarter 2025 Financial Results; Raises Full Year 2025 Adjusted EPS and Revenue Guidance

Comments

Humana

Noticias

Últimas noticias sobre Humana (NYSE:HUM) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL